Compass Therapeutics (CMPX) Cash from Financing Activities (2018 - 2026)
Compass Therapeutics (CMPX) reported Cash from Financing Activities of $3.4 million for Q1 2026, up 512.88% on a YoY basis from $549044.0 in Q1 2025, and up 216.56% sequentially from $1.1 million in Q4 2025.
Compass Therapeutics (CMPX) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Compass Therapeutics (CMPX) has 9 years of Cash from Financing Activities data on file, last reported at $3.4 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 512.88% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $133.8 million (up 14802.09% YoY), and the FY2025 full-year result was $129.6 million, up 647.54% from the prior year.
- Cash from Financing Activities improved to $3.4 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $129.4 million in Q3 2025 to a low of -$815000.0 in Q1 2025.
- A 5-year average of $16.4 million and a median of $31000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities plunged 109.52% in 2024 and jumped 6468150.0% in 2025, its largest moves.
- Tracing CMPX's Cash from Financing Activities over 5 years: stood at $75.8 million in 2022, then slumped by 100.21% to -$158000.0 in 2023, then jumped by 40.51% to -$94000.0 in 2024, then surged by 1230.85% to $1.1 million in 2025, then jumped by 216.56% to $3.4 million in 2026.
- Business Quant data shows CMPX's Cash from Financing Activities at $3.4 million in Q1 2026, $1.1 million in Q4 2025, and $129.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Compass Therapeutics | 395.17 Mn | 200.48 Mn | - | 3.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.37 Mn |
| Mar 31, 2026 | 3.37 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 129.36 Mn |
| Sep 30, 2025 | 129.36 Mn |
| Mar 31, 2025 | -815,000.00 |
| Mar 31, 2025 | -815,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | 17.43 Mn |
| Mar 31, 2024 | 17.43 Mn |
| Dec 31, 2023 | -158,000.00 |
| Dec 31, 2023 | -158,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Sep 30, 2023 | 21,000.00 |